184 related articles for article (PubMed ID: 12712335)
1. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
3. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations.
Moinfar F; Man YG; Lininger RA; Bodian C; Tavassoli FA
Am J Surg Pathol; 1999 Sep; 23(9):1048-58. PubMed ID: 10478664
[TBL] [Abstract][Full Text] [Related]
4. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
5. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
6. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
7. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?
Foster MC; Helvie MA; Gregory NE; Rebner M; Nees AV; Paramagul C
Radiology; 2004 Jun; 231(3):813-9. PubMed ID: 15105449
[TBL] [Abstract][Full Text] [Related]
8. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
9. [Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].
Piubello Q; Montemezzi S; D'Atri C
Pathologica; 2002 Dec; 94(6):299-305. PubMed ID: 12540993
[TBL] [Abstract][Full Text] [Related]
10. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
11. Rabbit monoclonal E-cadherin antibody: A cost-effective alternative to mouse monoclonal antibody in distinguishing ductal carcinoma in situ from lobular carcinoma in situ.
Baum JE; Croyle JA; Brodsky VB; Liu Y; Shin SJ
Breast J; 2019 Sep; 25(5):813-822. PubMed ID: 31165568
[TBL] [Abstract][Full Text] [Related]
12. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
Paredes J; Lopes N; Milanezi F; Schmitt FC
Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
[TBL] [Abstract][Full Text] [Related]
13. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization.
Jacobs TW; Pliss N; Kouria G; Schnitt SJ
Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072
[TBL] [Abstract][Full Text] [Related]
14. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
Lee AH
J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
[TBL] [Abstract][Full Text] [Related]
15. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy.
Berg WA; Mrose HE; Ioffe OB
Radiology; 2001 Feb; 218(2):503-9. PubMed ID: 11161169
[TBL] [Abstract][Full Text] [Related]
16. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up.
Mahoney MC; Robinson-Smith TM; Shaughnessy EA
AJR Am J Roentgenol; 2006 Oct; 187(4):949-54. PubMed ID: 16985141
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions.
Goldstein NS; Bassi D; Watts JC; Layfield LJ; Yaziji H; Gown AM
Am J Clin Pathol; 2001 Apr; 115(4):534-42. PubMed ID: 11293901
[TBL] [Abstract][Full Text] [Related]
19. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
Xu S; Wei B; Zhang H; Qing M; Bu H
Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
[TBL] [Abstract][Full Text] [Related]
20. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings.
Liberman L; Sama M; Susnik B; Rosen PP; LaTrenta LR; Morris EA; Abramson AF; Dershaw DD
AJR Am J Roentgenol; 1999 Aug; 173(2):291-9. PubMed ID: 10430122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
